Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

The Current Role of Measurable Residual Disease Testing (MRD):
Featuring Dr. Tara Graff & Dr. Brian Koffman

Measurable Residual Disease (MRD) testing is a highly sensitive laboratory test that can detect extremely small amounts of cancer cells that cannot be found by other conventional laboratory testing methods.

MRD testing has become increasingly important for those with CLL / SLL in determining the response to certain treatments, measuring the depth of remission after a treatment is complete, detecting when the cancer is returning even before symptoms are present, and in clinical trials it is being used to measure how well individuals have responded to therapies that are being investigated.

CLL Society has put together a learning activity that will help those with CLL / SLL learn about the role of MRD testing, gain an understanding of how it can be used as part of your disease management plan, and empower you to discuss its potential use with your healthcare provider.

You can begin the learning activity by answering the five questions below. After clicking submit, you will then be directed to an informative video interview and other CLL Society resources on MRD.